This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals Inc. closed 13.60% below its 52-week high of $26.16, which the company reached on March 24th.

BofA raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $34 from $33 and keeps a Buy rating on the shares. The firm, in its ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalyst Pharma (CPRX – Research Report), ...

Short interest in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) increased during the last reporting period, rising from 7.23M to 7.93M. This put 8.06% of the company's publicly available shares short.

National University of Singapore (NUS) chemists have developed an "anchoring-borrowing" strategy, combined with facet ...

In this article, we are going to take a look at where Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) stands against other best Russell 2000 stocks to buy according to Wall Street analysts. Since ...

Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains ...

President Donald Trump says he plans to impose tariffs on pharmaceuticals "very shortly," in what could be the next phase of his sweeping overhaul of global trade. President Donald Trump says he ...